ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.Targeted oncology · 2021Pooled it
- Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Guideline
- Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.The Cochrane database of systematic reviews · 2019Pooled it
- Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia.The Cochrane database of systematic reviews · 2016Pooled it
- Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.Health technology assessment (Winchester, England) · 2024Trial
- Trial
- Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Contribution of paranasal sinus, chest, and abdomen/pelvis computed tomography in patients with febrile neutropenia.PloS one · 2025Article
- The Effectiveness and Safety of Remdesivir Use in COVID-19 Patients with Neutropenia: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2024Article
- Septic shock in the immunocompromised cancer patient: a narrative review.Critical care (London, England) · 2024Review
- Development of a risk assessment scale for use by nurses to assess the risk of deep vein thrombosis in gynaecology in China: A Delphi-based study.Nursing open · 2023Article
- Clinical and microbiological profiles in post-chemotherapy neutropenic fever in hematological malignancy: exploration of clinical phenotype patterns by two-step cluster analysis.BMC infectious diseases · 2023Article
- Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.Annals of medicine · 2022Observational
- Mitigating acute chemotherapy-associated adverse events in patients with cancer.Nature reviews. Clinical oncology · 2022Review
- Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?The oncologist · 2022Review
- Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results.Cancers · 2022Article
- Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy.JNCI cancer spectrum · 2022Article
- Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study.IJID regions · 2021Article
- Effect of serum uric acid level and Multinational Association for Supportive Care in Cancer risk score on febrile neutropenia mortality.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Multinational Association for Supportive Care in Cancer risk index score developed, through a multinational collaboration, was published in 2000 with the aim to identify patients with chemotherapy-induced febrile neutropenia at low risk of serious medical complication development. It has been endorsed as a reliable tool since 2002 by Infectious Diseases Society of America. Ten years after, we thought worth to review its use, its characteristics in the external validations that occurred after the initial publication and also to review how the recognition of a group of patients at low risk has changed the management of febrile neutropenia. We also raise the issue of identification of high-risk patients that remains a challenge today.
Indexed as
Identifiers
23443617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.